Zynex Says FDA Clears M-Wave Neuromuscular Electrical Stimulation Device
(RTTNews) - Medical technology company Zynex, Inc. (ZYXI) announced Tuesday that it has received clearance from the U.S. Food and Drug Administration for the next generation M-Wave Neuromuscular Electrical Stimulation or NMES device.
NMES treatments have several uses, including aiding recovery from surgery, managing chronic conditions, and even enhancing exercise performance in healthy individuals.
The M-Wave replaces its predecessor, the E-Wave, which has been fundamental in NMES treatments across the U.S. since 1998.
The M-Wave is designed to improve the way patients manage their neuromuscular conditions. With advanced features and a user-friendly design, the M-Wave allows patients to be treated quickly in a clinical or home setting.
The compact and lightweight design of the M-Wave ensures portability and easy integration into patients' recovery routines.
KOSPI May Break Through 3,200-Point Level
Japan Data On Tap For Friday
Euro Climbs Against Majors
Swiss Market Ends Marginally Up
European Stocks Close Weak
Canadian Stocks Turning In Mixed Performance; TSX Down Marginally
U.S. Pending Home Sales Fall More Than Expected In July
